Alpha 2.0
Login Register
» Articles » PMID: 21453475

Quinupristin/dalfopristin in Staphylococcus Aureus Endophthalmitis: a Case Report

Overview
Journal J Med Case Rep
Publisher Biomed Central
Specialty General Medicine
Date 2011 Apr 2
PMID 21453475
Citations 7
Authors
Sergio E Hernandez-Da Mota
Affiliations
Soon will be listed here.
Abstract

Introduction: The intravitreal injection of antibiotics remains the mainstay of therapy for postoperative endophthalmitis. Bacterial resistance, however, is still a pitfall in achieving an adequate response to treatment. Quinupristin/dalfopristin might be a feasible therapeutic option in these cases.

Case Presentation: A 55-year-old Hispanic man had endophthalmitis secondary to Staphylococcus aureus in his right eye and was treated with intravitreal 0.4 mg/0.1 ml quinupristin/dalfopristin injection. Inflammation and pain remission were observed at four days after injection. The final best-corrected visual acuity was 20/40.

Conclusion: Although vancomycin remains the first-line intravitreal antibiotic therapy against infectious endophthalmitis caused by Gram-positive bacteria, quinupristin/dalfopristin exhibits similar efficacy and is theoretically more active against vancomycin-resistant strains, with no apparent retinal toxicity.

Citing Articles

Antimicrobial guide to posterior segment infections.

Patel T, Zacks D, Dedania V Graefes Arch Clin Exp Ophthalmol. 2020; 259(9):2473-2501.

PMID: 33156370 DOI: 10.1007/s00417-020-04974-4.

Emerging Worldwide Antimicrobial Resistance, Antibiotic Stewardship and Alternative Intravitreal Agents for the Treatment of Endophthalmitis.

Relhan N, Pathengay A, Schwartz S, Flynn Jr H Retina. 2017; 37(5):811-818.

PMID: 28338559 PMC: 5397345. DOI: 10.1097/IAE.0000000000001603.

Safety of intravitreal quinupristin/dalfopristin in an animal model.

Giordano V, Hernandez-Da Mota S, Adabache-Guel T, Castillejos-Chevez A, Corredor-Casas S, Salinas-Longoria S Int J Ophthalmol. 2016; 9(3):373-8.

PMID: 27158605 PMC: 4844051. DOI: 10.18240/ijo.2016.03.08.

Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment.

Relhan N, Albini T, Pathengay A, Kuriyan A, Miller D, Flynn H Br J Ophthalmol. 2015; 100(4):446-52.

PMID: 26701686 PMC: 5541392. DOI: 10.1136/bjophthalmol-2015-307722.

Pharmacokinetics of intravitreal antibiotics in endophthalmitis.

Radhika M, Mithal K, Bawdekar A, Dave V, Jindal A, Relhan N J Ophthalmic Inflamm Infect. 2015; 4:22.

PMID: 25667683 PMC: 4306439. DOI: 10.1186/s12348-014-0022-z.

References
1.
Smith M, Sorenson J, DAVERSA G, Mandelbaum S, Udell I, Harrison W . Treatment of experimental methicillin-resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin and intravitreal dexamethasone. J Infect Dis. 1997; 175(2):462-6. DOI: 10.1093/infdis/175.2.462. View
2.
. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995; 113(12):1479-96. View
3.
LORIAN V, Fernandes F . Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium. J Antimicrob Chemother. 1997; 39 Suppl A:63-6. DOI: 10.1093/jac/39.suppl_1.63. View
4.
Baum J, Peyman G, Barza M . Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv Ophthalmol. 1982; 26(4):204-6. DOI: 10.1016/0039-6257(82)90080-7. View
5.
Finch R . Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs. 1996; 51 Suppl 1:31-7. DOI: 10.2165/00003495-199600511-00007. View